Trial Profile
A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 14 Jan 2020 Planned number of patients changed from 30 to 13.
- 14 Jan 2020 Planned End Date changed from 31 Jan 2025 to 31 Jan 2022.